ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Nonsteroidal antiinflammatory drugs (NSAIDs)"

  • Abstract Number: 0540 • ACR Convergence 2024

    Nonsteroidal Anti-Inflammatory Drug Use and Incident Hypertension Among Patients with Axial Spondyloarthritis

    Jose Meade Aguilar1, Jean Liew2, Rachael Stovall3, Sofia Ramiro4 and Lianne S Gensler5, 1Boston Medical Center, Boston, MA, 2Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 3University of Washington, Seattle, 4Leiden University Medical Center, Bunde, Netherlands, 5Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA

    Background/Purpose: Patients with axial spondyloarthritis (axSpA) have a heightened risk of cardiovascular morbidity and mortality. Nonsteroidal anti-inflammatory drugs (NSAIDs) are first line treatment for axSpA,…
  • Abstract Number: 1446 • ACR Convergence 2024

    Is the Remission Achieved with Asdas, Basdaı a Real Remission? Should Ultrasound Be Added to the Parameters?

    Emrah Koç1, Burak Okyar2, Sibel Bakırcı3, suade Özlem Badak2, Ali Nail Demir4, İsmail Uçar4, Gökhan Sargın5, Servet Yüce6 and Emine Duygu Ersözlü1, 1Adana City Training and Research Hospital, Adana, Turkey, 2Adana City Training and Research Hospital, Adana, 3Antalya training and research hospital, Antalya, Turkey, 4Mersin City Hospital, Mersin, Turkey, 5Aydin Adnan Menderes University, Aydın, Turkey, 6Şırnak Provincial Health Directorate Public Health Department, Şırnak, Turkey

    Background/Purpose: The study aimed to evaluate changes in enthesis areas in ankylosing spondylitis patients in remission for at least six months, using either NSAIDs or…
  • Abstract Number: 1476 • ACR Convergence 2024

    Individualizing NSAIDs in Axial Spondyloarthritis Through a Series of N-of-1 Clinical Trials with Bayesian Analysis

    Mark Hwang1, Seokhun Kim2, Shervin Assassi3, Joyce Samuel4, Charles Green2, Jon Tyson4 and John Reveille5, 1Department of Internal Medicine, Division of Rheumatology, John P. and Katherine G. McGovern School of Medicine, UTHealth Houston, Houston, TX, 2UTHealth Houston, Houston, 3UTHealth Houston Division of Rheumatology, Houston, TX, 4UTHealth Houston, Houston, TX, 5UTHealth Houston Division of Rheumatology, Houston

    Background/Purpose: Nonsteroidal anti-inflammatory drugs (NSAIDs) are first line pharmacological treatment for Axial Spondyloarthritis (axSpA), yet individual responses to different NSAIDs vary significantly. This study aims…
  • Abstract Number: 2091 • ACR Convergence 2024

    Changes in Analgesic Prescriptions for the Treatment of Osteoarthritis During the COVID-19 Pandemic

    Derek Ochi1, Dagoberto Pina2, Manmeet Kaur3, Jeffery Fine4, Daniel Black5 and Barton Wise6, 1Division of Rheumatology, Allergy and Clinical Immunology, University of California Davis, Sacramento, CA, 2School of Medicine, University of California Davis, Sacramento, CA, 3Division of Rheumatology, Allergy and Immunology, University of California San Diego, San Diego, CA, 4Department of Public Health Sciences, University of California Davis, Sacramento, CA, 5Innovation Technology - Data Center of Excellence, University of California Davis, Sacramento, CA, 6Division of Rheumatology, Allergy and Clinical Immunology, University of California Davis and Department of Orthopaedic Surgery, University of California Davis, Sacramneto, CA

    Background/Purpose: Osteoarthritis (OA) is a leading cause of disability. The 2019 American College of Rheumatology (ACR)/Arthritis Foundation (AF) Guideline for the Management of OA recommends…
  • Abstract Number: 2317 • ACR Convergence 2024

    Chronic Kidney Disease in Patients with Psoriatic Arthritis: A Cohort Study

    Fadi Kharouf1, Shangyi Gao2, Shahad Al-Matar3, Daniel Pereira4, Richard Cook5, Vinod Chandran6 and Dafna Gladman7, 1University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, 2Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, 3Toronto Western Hospital, University of Toronto, Toronto, Canada, 4University Health Network, Toronto, ON, Canada, 5University of Waterloo, Waterloo, Canada, 6University of Toronto, Toronto, ON, Canada, 7University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Chronic kidney disease (CKD) is a comorbidity in psoriatic arthritis (PsA). In this study, we aimed to define the prevalence of CKD in patients…
  • Abstract Number: 2343 • ACR Convergence 2024

    Temporal Trends in and Associations with NSAID Prescription in Adult and Pediatric Patients with IBD

    Adam Mayer1, Rui Xiao2, Andrew Grossman3, Meenakshi Bewtra4, Michael George2 and Pamela Weiss5, 1University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA, 3Children's Hospital of Philadelphia, Philadelphia, 4University of Pennsylvania, Philadelphia, 5Children's Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: The role of nonsteroidal anti-inflammatory drugs (NSAIDs) in the management of musculoskeletal symptoms in patients with inflammatory bowel disease (IBD) and IBD-associated arthritis remains…
  • Abstract Number: 2346 • ACR Convergence 2024

    Treatment Effect on Predictors of Ankylosis in Axial Spondyloarthritis

    Pauline KRUG1, Anthony Lichaa1 and Adrien Nzeusseu Toukap2, 1Cliniques universitaires St-Luc, Brussel, Belgium, 2Cliniques universitaires Saint-Luc,, St.-Lambrechts-Woluwe, Belgium

    Background/Purpose: Axial spondyloarthritis (axSpA) is a progressive chronic inflammatory disease. In its early stages, symptoms appear without radiographic evidence. Later, structural lesions are observed on…
  • Abstract Number: 0374 • ACR Convergence 2023

    Actionable Adverse Events in a Real-Practice Cohort of Children with Juvenile Idiopathic Arthritis. Results from the CAPRI Registry

    Bashayer Alnuaimi1, Michelle Batthish2, Roberta A Berard3, Gilles Boire4, Sarah Campillo1, Amieleena Chhabra5, Julie Couture6, Paul Dancey7, Brian Feldman8, Tommy Gerschman9, Julie Herrington10, Kristin Houghton11, Adam Huber12, Claire LeBlanc1, Lillian Lim13, Jean-Philippe Proulx-Gauthier6, Heinrike Schmeling14, Rosie Scuccimarri1, Lori Tucker15, Jaime Guzman15, Gaëlle Chédeville1 and For The CAPRI Registry Investigators16, 1McGill University Health Center, Montreal, QC, Canada, 2McMaster Children's Hospital, Hamilton, ON, Canada, 3Children's Hospital - London Health Sciences Centre, London, ON, Canada, 4Université de Sherbrooke, Sherbrooke, QC, Canada, 5British Columbia Hospital, Vancouver, BC, Canada, 6CHU de Quebec- Universite Laval, Quebec City, QC, Canada, 7Memorial University of Newfoundland, St. John's, NL, Canada, 8The Hospital for Sick Children, Toronto, ON, Canada, 9British Columbia Children's Hospital, Burnaby, BC, Canada, 10McMaster University, Hamilton, ON, Canada, 11British Columbia University, Vancouver, BC, Canada, 12IWK Health Centre, Halifax, NS, Canada, 13University of Alberta, Edmonton, AB, Canada, 14University of Calgary, Calgary, AB, Canada, 15British Columbia Children's Hospital, Vancouver, BC, Canada, 16CAPRI, Montreal, QC, Canada

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic inflammatory rheumatic disease of childhood and most children require long-term treatment. Adverse events (AE) during…
  • Abstract Number: 0533 • ACR Convergence 2023

    Remission in Axial Spondyloarthritis: Is There a Difference Between NSAIDs and b/tsDMARDs in Daily Practice?

    Francesco Natalucci1, Pauline KRUG2, Angela DE SOUSA LEITE2, Tatiana Sokolova3, Patrick Durez4, Maria S. Stoenoiu2 and Adrien NZEUSSEU TOUKAP5, 1UCLouvain University, Sermoneta, Italy, 2Cliniques Universitaires Saint-Luc, Brussels, Belgium, 3Université Catholique de Louvain, Brussels, Belgium, 4UCLouvain, Brussels, Belgium, 5Cliniques universitaires Saint-Luc, St.-Lambrechts-Woluwe, Belgium

    Background/Purpose: Randomized-controlled trials (RCTs) done in axial spondyloarthritis (axSpA) patients have shown that remission in axSpA (including nonradiographic axSpA) patients treated without b/tsDMARDs (TNFα blockers,…
  • Abstract Number: 1196 • ACR Convergence 2023

    Association of Long-Term Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) with Worsening Symptoms and Structural Changes of Knee Osteoarthritis: An Individual Patient Data Meta-Analysis of Cohort Studies

    Zubeyir Salis1 and Amanda Sainsbury2, 1The University of New South Wales, Kensington, Australia, 2The University of Western Australia, Crawley, Australia

    Background/Purpose: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are commonly prescribed for short-term management of symptoms of knee osteoarthritis (KOA), but they are often used long-term, and the…
  • Abstract Number: 1394 • ACR Convergence 2023

    Comorbidities, Not Long-Term Use of Nonsteroidal Anti-Inflammatory Drugs, May Be Associated with Chronic Kidney Disease in Patients with Ankylosing Spondylitis: A Nationwide Population-Based Study

    Bon San Koo1, Subin Hwang1, Ye-Jee Kim2, Soo Min Ahn2 and Wook Jang Seo3, 1Inje University Seoul Paik Hospital, Seoul, South Korea, 2Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, 3Department of Rheumatology, Veteran Health Service Medical Center, Seoul, South Korea

    Background/Purpose: Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed as first-line treatment for symptom relief and inflammation reduction in patients with ankylosing spondylitis (AS). However, long-term…
  • Abstract Number: 2053 • ACR Convergence 2023

    Predictive Factors Associated with Treatment Response in Chronic Nonbacterial Osteomyelitis

    Katherine Nowicki1, Nathan Rogers2, Carson Keeter2, Nathan Donaldson2, Jennifer Soep2 and Yongdong (Dan) Zhao3, 1University of Colorado, Lakewood, CO, 2University of Colorado, Aurora, CO, 3University of Washington, Redmond, WA

    Background/Purpose: Chronic nonbacterial osteomyelitis (CNO) is characterized by sterile inflammatory bone lesions and most commonly affects skeletally immature children. Non-steroidal anti-inflammatory drugs (NSAIDs) are the…
  • Abstract Number: 2565 • ACR Convergence 2023

    The Problem of Pain in Rheumatology: A Population-based Study of Annual Trends in Pain Management Modalities in Patients with Autoimmune Rheumatic Diseases in the United States, 2007-2021

    Titilola Falasinnu1, Di Lu2 and Matthew Baker3, 1Stanford School of Medicine, Palo Alto, CA, 2Stanford School of Medicine, Stanford, CA, 3Stanford University, Menlo Park, CA

    Background/Purpose: Autoimmune rheumatic diseases (ARD) such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are salient causes of disability, functional limitations, reduced quality of…
  • Abstract Number: 048 • 2023 Pediatric Rheumatology Symposium

    Comparative Efficacy and Safety of Ibuprofen and Naproxen in the Treatment of Oligoarticular Juvenile Idiopathic Arthritis (oJIA): Bi-national Cohort Study

    Orly Ohana1, Itay Marmor2, Liora Harel3, Shiri Rubin4, rotem tal5, Yoel Levinsky6, Orit Peled7 and Gil Amarilyo3, 1Pediatric C ward, Schneider Children's Medical Centre, Petach Tikva, Israel, 2Dana-Dwek Children's Hospital, Hod Hasharon, Israel, 3Pediatric rheumatology clinic, Schneider children's medical center of Israel, Petach Tikva, Israel, 4Pediatric Ear Nose and Throat Unit Unit, Schneider Children's Medical Center of Israel, Petach Tikva, Israel, 5Schneider Children's Medical Center of Israel, Petach Tikva, Israel, 6Schneider Children's Medical Center of Israel, Tel Aviv University, Petach Tikva, Israel, 7Department of Pharmacy, Schneider Children's Medical Center of Israel, Petach Tikva, Israel

    Background/Purpose: JIA is the most common childhood rheumatic disease. NSAIDs and intraarticular corticosteroid injections (IACI) are first-line therapy for oJIA. NSAIDs Adverse events (AEs) include…
  • Abstract Number: 1809 • ACR Convergence 2022

    Impact of Colchicine Prophylaxis on Cardiovascular Outcome Among Gout Patients: A Secondary Analysis of CARES Trial

    Keigo Hayashi1, yuqing zhang2, Hyon Choi3 and Kazuki Yoshida4, 1Brigham and Women's Hospital, Okayama, Japan, 2Massachusetts General Hospital, Quincy, MA, 3MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, 4Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Low-dose colchicine has been demonstrated to reduce cardiovascular (CV) events in two recent large cardiovascular trials. Gout patients, for whom colchicine is a highly relevant…
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology